In re Niaspan Antitrust Litig., No. 13-cv-1820 (E.D. Pa.)
In re Niaspan Antitrust Litig., No. 13-cv-1820 (E.D. Pa.)
In the Niaspan case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Abbott Laboratories’ triglyceride drug, Niaspan, whose active ingredient is niacin (vitamin B6). Faruqi & Faruqi filed the first direct purchase
In the Niaspan case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Abbott Laboratories’ triglyceride drug, Niaspan, whose active ingredient is niacin (vitamin B6). Faruqi & Faruqi filed the first direct purchaser complaint in this case. The case alleges that the successive brand manufacturers of Niaspan (Kos, Abbott, Abbvie) paid successive would-be generic competitors (Duramed, Barr, and Teva) to delay launching less-expensive generic versions of Niaspan, in what is commonly known as a “pay-for-delay” conspiracy.
